Canlyniadau Chwilio - Inja Waldhauer

  • Dangos 1 - 11 canlyniadau o 11
Mireinio'r Canlyniadau
  1. 1
    Tumor-Associated MICA Is Shed by ADAM Proteases

    Tumor-Associated MICA Is Shed by ADAM Proteases gan Inja Waldhauer, Dennis Goehlsdorf, Friederike Gieseke, Toni Weinschenk, Mareike Wittenbrink, Andreas Ludwig, Stefan Stevanović, Hans‐Georg Rammensee, Alexander Steinle

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

    Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose gan Claudia Ferrara, Sandra Grau, Christiane Jäger, Peter Sondermann, Peter Brünker, Inja Waldhauer, Michael Hennig, A. Ruf, Arne C. Rufer, M. Stihle, Pablo Umaña, Jörg Benz

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents

    A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents gan Sylvia Herter, Laura Morra, Ramona Schlenker, Jitka Šulcová, Linda Fahrni, Inja Waldhauer, Steffi Lehmann, Timo Reisländer, Irina Agarkova, Jens M. Kelm, Christian Klein, Pablo Umaña, Marina Bacac

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells

    Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells gan John Cha, Yongliang Sun, Urszula Nowak, Jan Clark, Sarah Howlett, Marcin Ł. Pękalski, Xin Yang, Oliver Ast, Inja Waldhauer, Anne Freimoser–Grundschober, Ekkehard Moessner, Pablo Umaña, Christian Klein, Ralf J. Hosse, Linda S. Wicker, Laurence B. Peterson

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

    A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease gan Laurence B. Peterson, John Cha, Sarah Howlett, Marcin Ł. Pękalski, Kevin Brady, Heather Hinton, Denise Sauter, John A. Todd, Pablo Umaña, Oliver Ast, Inja Waldhauer, Anne Freimoser–Grundschober, Ekkehard Moessner, Christian Klein, Ralf J. Hosse, Linda S. Wicker

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti–Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis

    Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti–Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis gan Peter Laverman, Tessa van der Geest, Samantha Y.A. Terry, Danny Gerrits, Birgitte Walgreen, Monique M. Helsen, Tapan K. Nayak, Anne Freimoser–Grundschober, Inja Waldhauer, Ralf J. Hosse, Ekkehard Moessner, Pablo Umaña, Christian Klein, Wim J.G. Oyen, Marije I. Koenders, Otto C. Boerman

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

    Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models gan Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin van Puijenbroek, Sabine M. Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo Umaña, Gerhard Niederfellner, Marina Bacac, Christian Klein

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

    RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis gan Peter Brünker, Katharina Wartha, Thomas Friess, Sandra Grau-Richards, Inja Waldhauer, Claudia Ferrara, Barbara Weiser, Meher Majety, Valeria Runza, Huifeng Niu, Kathryn Packman, Ningping Feng, Sherif Daouti, Ralf J. Hosse, Ekkehard Mössner, Thomas G. Weber, Frank Herting, Werner Scheuer, Hadassah Sade, Cuiying Shao, Bin Liu, Peng Wang, Gary Xu, Suzana Vega-Harring, Christian Klein, Klaus Bosslet, Pablo Umaña

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

    Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy gan Inja Waldhauer, Valeria Gonzalez‐Nicolini, Anne Freimoser–Grundschober, Tapan K. Nayak, Linda Fahrni, Ralf J. Hosse, Danny Gerrits, E.J. Geven, Johannes Sam, Sabine M. Lang, Esther Bommer, Virginie Steinhart, Elisabeth Husar, Sara Colombetti, Erwin van Puijenbroek, Markus Neubauer, J. Mark Cline, Pradeep Garg, Gregory O. Dugan, Federica Cavallo, Gonzalo Acuña, Jehad Charo, Volker Teichgräber, Stefan Evers, Otto C. Boerman, Marina Bacac, Ekkehard Moessner, Pablo Umaña, Christian Klein

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

    Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional I... gan Christian Klein, Inja Waldhauer, Valeria Nicolini, Anne Freimoser–Grundschober, Tapan K. Nayak, Daniëlle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, M. Stihle, Sabine M. Lang, Michaele Roemmele, Thomas Höfer, Erwin van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina De Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus A.M.S. van Dongen, Ekkehard Moessner, Pablo Umaña

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

    PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells gan Laura Codarri, Valeria Nicolini, Masao Hashimoto, Maria Karagianni, Petra Schwalie, Laura Lauener, Eleni Maria Varypataki, Marine Richard, Esther Bommer, Johannes Sam, Stefanie Joller, Mario Perro, Floriana Cremasco, Leo Kunz, Emilio Yángüez, Tamara Hüsser, Ramona Schlenker, Marisa Mariani, Vinko Toševski, Sylvia Herter, Marina Bacac, Inja Waldhauer, Sara Colombetti, Xavier Guéripel, Stephan Wullschleger, Mélanie Tichet, Douglas Hanahan, Haydn Kissick, Stéphane Leclair, Anne Freimoser–Grundschober, Stefan Seeber, Volker Teichgräber, Rafi Ahmed, Christian Klein, Pablo Umaña

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: